跳至主要内容
临床试验/NCT07661446
NCT07661446尚未招募1 期

Cannabis and Opioid Use Disorder, Study 2

University of Kentucky1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年10月1日最近更新:
干预措施
相关药物

试验速览

阶段
1 期
状态
尚未招募
入组人数
100
试验地点
1
主要终点
Opioid withdrawal severity

研究概览

简要总结

This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Participants with moderate to severe opioid use disorder

排除标准

  • Individuals who do not use opioids or do not experience opioid withdrawal when they stop using opioids

研究组 & 干预措施

Oral cannabis (active)

Experimental

Participants will receive active oral cannabis

干预措施: Intranasal Opioid (Drug)

Oral cannabis (placebo)

Placebo Comparator

Participants will receive placebo oral cannnabis

干预措施: Inhaled Cannabis (Drug)

Oral cannabis (placebo)

Placebo Comparator

Participants will receive placebo oral cannnabis

干预措施: Intranasal Opioid (Drug)

Oral cannabis (active)

Experimental

Participants will receive active oral cannabis

干预措施: Inhaled Cannabis (Drug)

结局指标

主要结局

Opioid withdrawal severity

时间窗: This outcome will be assessed regularly from baseline through 6 hours post cannabis dose during experimental sessions.

Opioid severity is a participant-rated outcome that will be measured on a visual analog scale (0-100)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shanna Babalonis, PhD

Associate Professor

University of Kentucky

研究点 (1)

Loading locations...

相似试验